Pomerantz LLP is investigating claims on behalf of investors of GenMark Diagnostic, Inc. ("GenMark" or the "Company") (NASDAQ: GNMK). Such investors are advised to contact Robert S. Willoughby at email@example.com or 888-476-6529, ext. 9980.
The investigation concerns whether GenMark and certain of its officers and/or directors have engaged in securities fraud or other unlawful business practices.
On November 2, 2017, GenMark President and Chief Executive Officer Hany Massarany stated during an earnings conference call that revenue recognition for expected placements of the Company's ePlex product was slowed by a longer-than-expected customer evaluation and validation process prior to implementation of ePlex in routine clinical use. On this news, shares of GenMark have fallen as much as $2.63, or 36.23%, during intraday trading on November 3, 2017.